Posters & Publications

OBA: a phase 2 clinical trial testing the drug candidate BIO101 (20E) to limit the loss of muscle mass and function induced by semaglutide in patients with obesity.

Waly Dioh PhD, MBA Chief Clinical Officer

BIO101, a drug candidate to counter-act age-related sarcopenia: towards Phase 3 program.

Waly Dioh PhD, Cendrine Tourette, PhD, Sandrine Rabut, PharmD, Roger Fielding, PhD, Jean Mariani, MD, PhD, Rob Van Maanen, MD and Stanislas Veillet, PhD

Biophytis BIO101 in Sarcopenia: results of the Phase 2 SARA-INT study. Oral presentation at 2nd Geroscience Conference, Mar 24-25th, Toulouse, France.

Tourette C., Dioh W., Margalef C., Azbekyan A., Lafont R., Dilda P., Mariani J., Del Signore S., Agus S., Van Maanen R., Veillet S. (2022).

Biophytis BIO101 in Sarcopenia: Results of the SARA Program. Oral presentation at ICFSR 2022, Boston Apr 20th – 22nd. The Journal of Frailty & Aging, in press.

Tourette C., Dioh W., Margalef C., Azbekyan A., Rabut S., Dupont P., Lafont R., Dilda P., Mariani J., Agus S., Van Maanen R., Veillet S. (2022).

BIO101 in age-related sarcopenia: Results of the SARA program. Oral presentation at 15th SCWD international conference, Lisbon June 24th-26th. Journal of Cachexia, Sarcopenia and Muscle, in press.

Tourette C., Dioh W., Margalef C., Azbekyan A., Rabut S., Dupont P., Lafont R., Dilda P., Mariani J., Agus S., Van Maanen R., Veillet S. (2022).

SARA program: the use of BIO101, a MAS receptor agonist, for the treatment of sarcopenia. Industry sponsored session, annual digital meeting of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD).

Tourette et al.

SARA program: Preliminary Findings & Implications from SARA-OBS Study and Its Impact on SARA-INT Study.

Dioh et al. Poster presented at 2nd International Summit on Aging & Gerontology (Aging & Gerontology-2020) 15-16th June, London, UK.

SARA program: Preliminary Findings & Implications from SARA-OBS Study and Its Impact on SARA-INT Study.

Dioh et al. Poster presented at ICFSR 2020, 11-13 Mar, Toulouse, France.

SARA program: Preliminary Findings from SARA-OBS study and impacts on the SARA-INT study design.

Dioh et al. Oral presentation at SCWD conference on cachexia, sarcopenia and muscle wasting. December 6-8th, Berlin, Germany. Abstract published in Journal of Cachexia, Sarcopenia and Muscle.

Evaluation of safety and efficacy of BIO101, a new investigational drug for Sarcopenia: a double-blind, placebo controlled, randomized clinical trial.

Dioh et al. Oral presentation at 10th International Conference on Frailty & Sarcopenia Research (ICFSR), February 20-22, 2019, Miami, USA. Abstract in press in The Journal of Frailty & Aging.

Designing a clinical program for BIO101, a Mas receptor activator to target Age-related sarcopenia.

Dioh et al. Oral presentation at 10th International Conference on Frailty & Sarcopenia Research (ICFSR), February 20-22, 2019, Miami, USA.

Transitioning from SARA-OBS, an observational study to SARA-INT, a double-blind, placebo controlled, randomized clinical trial to evaluate safety and efficacy of Sarconeos (BIO101).

Dioh et al. Oral presentation at the 11th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 7-9, 2018, Maastricht, Netherlands. Abstract published in Journal of Cachexia, Sarcopenia and Muscle 2018 Dec; 9(6); 1172. Abstract 5-01.

Effects of Sarconeos (API BIO101) on in vivo and in vitro models of Duchenne muscular dystrophy.

Dilda et al. Poster presentation at the 23rd International Annual Congress of the World Muscle Society (WMS), October 3-7, 2018, Mendoza, Argentina. Abstract published in Neuromuscular Disorders, 28 (Suppl.2) S143, P206.

SARA-INT, A double-blind, placebo controlled, randomized clinical trial to evaluate safety and efficacy of Sarconeos (BIO101).

Dioh et al. Poster presentation at the 9th International Conference on Frailty & Sarcopenia Research (ICFSR), March 1-3, 2018, Miami, USA.

SARA-OBS, an observational study dedicated to characterize Age-related Sarcopenia population suitable for interventional studies.

Dioh et al. Oral presentation at the 9th International Conference on Frailty & Sarcopenia Research (ICFSR), March 1-3, 2018, Miami, USA. Abstract published in The Journal of Frailty & Aging, 7(1), 72. Abstract OC44.

Daily Mobility profile in Age-Related Sarcopenia: Actimetry baseline data from SARA-OBS, a six-month observational multicentre clinical study in EU and US.

Zia et al. Poster presentation at the 9th International Conference on Frailty & Sarcopenia Research (ICFSR), March 1-3, 2018, Miami, USA. Abstract published in The Journal of Frailty & Aging, 7(1), 128. Abstract P110.

BIO103 demonstrates sharp improvement of skeletal muscle function in an animal model of hindlimb immobilization.

Latil et al. Poster presentation at the 9th International Conference on Frailty & Sarcopenia Research (ICFSR), March 1-3, 2018, Miami, USA. Abstract published in The Journal of Frailty & Aging, 7(1), 128-129. Abstract P113.

SARA clinical program for evaluating safety and efficacy of Sarconeos in a Phase 2b clinical trial.

Dioh et al. Poster presentation at the 10th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 8-10, 2017, Rome, Italy. Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 8, 1073-1074. Abstract 9-02.

SARA-PK: A single and multiple ascending oral doses study to assess the safety and evaluate the pharmacokinetics of BIO101 in healthy young and older volunteers.

Dioh et al. Oral and poster presentations at the 8th International Conference on Frailty & Sarcopenia Research (ICFSR), April 27-29, 2017, Barcelona, Spain. Abstract published in The Journal of Frailty & Aging. 6(S1), 28, Abstract OC38.

BIO101, a drug candidate targeting Mas Receptor for the treatment of age-related muscle degeneration. From molecular target identification to clinical development.

Dilda et al. Poster presentation at the 9th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 10-11, 2016, Berlin, Germany. Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 7(5), 655. Abstract 4-01.

A randomized, placebo-controlled trial to evaluate the efficacy and safety of BIO101 on Sarcopenic Obesity.

Dioh et al. Poster presentation at the 7th International Conference on Frailty & Sarcopenia Research (ICFSR), April 28-29, 2016, Philadelphia, USA. Abstract published in The Journal of Frailty & Aging, 5, S1, 75, Abstract P53.

BIO101, a drug candidate targeting sarcopenic obesity through MAS receptor activation. Raynal et al.

Poster presentation at the 8th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 4-6, 2015, Paris, France. Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 6(4), 429. Abstract 1-76.

海报与出版物

长寿平台

BIO101 治疗肌肉减少症

BIO101 治疗肥胖症

BIO101 用于 COVID-19

BIO101 治疗杜氏肌营养不良症

BIO203 治疗黄斑变性

其他

长寿平台

20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor.

Ecysteroid metabolism in mammals: the fate of ingested 20-hydroxyecdysone in mice and rats.

The complex metabolism of poststerone in male rats.

20-Hydroxyecdysone, from Plant Extracts to Clinical Use: Therapeutic Potential for the Treatment of Neuromuscular, Cardio-Metabolic and Respiratory Diseases.

Small-scale analysis of phytoecdysteroids in seeds by HPLC/DAD/MS for the identification and quantification of specific analogues, dereplication and chemotaxonomy.

Dietary phytoecdysteroids. Dinan et al. Chapter 5 of Handbook of Dietary Phytochemicals. J.

SARCONEOS (API BIO101) targets Mas receptor within the protective arm of the renin angiotensin system and proves efficacy in various models of muscle wasting.

BIO101 accelerates differentiation and enhances mitochondrial function in skeletal muscle cells.

Combined effects of BIO101 on anabolism and mitochondrial function in skeletal muscle cells.

BIO103, a drug candidate for the treatment of muscle wasting disorders.

BIO103, a second-generation compound for the treatment of sarcopenia. From anabolic properties to the reversion of aging-related functional loss.

The SARCOB program: a french consortium for developing drug candidate and nutraceutical targeting sarcopenic obesity.

BIO101 治疗肌肉减少症

OBA: a phase 2 clinical trial testing the drug candidate BIO101 (20E) to limit the loss of muscle mass and function induced by semaglutide in patients with obesity.

BIO101, a drug candidate to counter-act age-related sarcopenia: towards Phase 3 program.

Biophytis BIO101 in Sarcopenia: results of the Phase 2 SARA-INT study. Oral presentation at 2nd Geroscience Conference, Mar 24-25th, Toulouse, France.

Biophytis BIO101 in Sarcopenia: Results of the SARA Program. Oral presentation at ICFSR 2022, Boston Apr 20th – 22nd. The Journal of Frailty & Aging, in press.

BIO101 in age-related sarcopenia: Results of the SARA program. Oral presentation at 15th SCWD international conference, Lisbon June 24th-26th. Journal of Cachexia, Sarcopenia and Muscle, in press.

SARA program: the use of BIO101, a MAS receptor agonist, for the treatment of sarcopenia. Industry sponsored session, annual digital meeting of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD).

SARA program: Preliminary Findings & Implications from SARA-OBS Study and Its Impact on SARA-INT Study.

SARA program: Preliminary Findings & Implications from SARA-OBS Study and Its Impact on SARA-INT Study.

SARA program: Preliminary Findings from SARA-OBS study and impacts on the SARA-INT study design.

Evaluation of safety and efficacy of BIO101, a new investigational drug for Sarcopenia: a double-blind, placebo controlled, randomized clinical trial.

Designing a clinical program for BIO101, a Mas receptor activator to target Age-related sarcopenia.

Transitioning from SARA-OBS, an observational study to SARA-INT, a double-blind, placebo controlled, randomized clinical trial to evaluate safety and efficacy of Sarconeos (BIO101).

Effects of Sarconeos (API BIO101) on in vivo and in vitro models of Duchenne muscular dystrophy.

SARA-INT, A double-blind, placebo controlled, randomized clinical trial to evaluate safety and efficacy of Sarconeos (BIO101).

SARA-OBS, an observational study dedicated to characterize Age-related Sarcopenia population suitable for interventional studies.

Daily Mobility profile in Age-Related Sarcopenia: Actimetry baseline data from SARA-OBS, a six-month observational multicentre clinical study in EU and US.

BIO103 demonstrates sharp improvement of skeletal muscle function in an animal model of hindlimb immobilization.

SARA clinical program for evaluating safety and efficacy of Sarconeos in a Phase 2b clinical trial.

SARA-PK: A single and multiple ascending oral doses study to assess the safety and evaluate the pharmacokinetics of BIO101 in healthy young and older volunteers.

BIO101, a drug candidate targeting Mas Receptor for the treatment of age-related muscle degeneration. From molecular target identification to clinical development.

A randomized, placebo-controlled trial to evaluate the efficacy and safety of BIO101 on Sarcopenic Obesity.

BIO101, a drug candidate targeting sarcopenic obesity through MAS receptor activation. Raynal et al.

BIO101 治疗肥胖症

BIO101 + GLP-1RA to prevent potential muscle loss in patients with overweight and obesity: the OBA study

BIO101: a drug candidate to reduce GLP-1RA-induced muscle mass or function loss in patients with obesity

Optimising Obesity Clinical Trials: From Site Selection to Patient Reach, BIO101 + GLP-1RA to prevent muscle loss in patients with overweight and obesity: the OBA study

BIO101 用于 COVID-19

Efﬁcacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial

COVA clinical study: Results from a double-blind, placebo-controlled phase 2/3 study to assess efficacy and safety of BIO101 in hospitalized severe COVID-19 patients.

COVA study: results from a double-blind, placebo-controlled phase 2/3 study to assess efficacy and safety of BIO101 in hospitalized COVID-19 patients.

COVA clinical study: Results from a double-blind, placebo-controlled phase 2/3 study to assess efficacy and safety of BIO101 in hospitalized severe COVID-19 patients.

Discussing the use of Sarconeos (BIO101) for the treatment of an emerging age-related disease, Covid-19. 4th Annual Longevity Therapeutics Summit, June 28th-30th, San Francisco.

A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality.

Preclinical efficacy of BIO101 on respiratory function in SARS-CoV-2-infected Syrian hamsters.

Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomized controlled trial.

Developing new drugs activating the protective arm of the Renin Angiotensin System as a potential treatment of respiratory failure in COVID-19 patients.

BIO101 治疗杜氏肌营养不良症

Results of two clinical trials in vulnerable populations support the evaluation of BIO101 (20-hydroxyecdysone), a MAS Receptor activator as a candidate oral treatment for rare pediatric neuromuscular diseases

BIO101 drug candidate development in rare neuromuscular diseases: Cardiorespiratory and motor unit preclinical evaluation in DMD and in SMA

BIO101 as a candidate oral treatment for DMD patients is supported by the results of two randomized clinical trials in vulnerable populations

Preclinical characterization of Sarconeos (API BIO101) in Duchenne muscular dystrophy.

The MYODA Operational Seamless clinical trial design phase I to III: A new approach for Rare Diseases to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of BIO101 (MAS Activator) in Pediatric Patients with a Genetically Confirmed Diagnosis of Duchenne Muscular Dystrophy (DMD).

MYODA clinical program: Composite score for assessing the efficacy of BIO101 (MAS activator) in ambulatory and non-ambulatory Duchenne boys.

The MYODA seamless clinical trial design: a true innovation for rare diseases including DMD.

MYODA clinical program: A new approach unravelling drug effects through a composite outcome score encompassing ambulant to non-ambulant disease stages.

BIO101 demonstrates combined beneficial effects on skeletal muscle and respiratory functions in a mouse model of Duchenne muscular dystrophy.

Preclinical characterization of Sarconeos (API BIO101) in Duchenne muscular dystrophy.

Sarconeos, a drug candidate in clinical development for Sarcopenia, demonstrates sharp functional improvement and anti-fibrotic properties in an animal model of Duchenne muscular dystrophy.

BIO203 治疗黄斑变性

Structural Analysis of Unstable Norbixin Isomers Guided by Pure-Shift Nuclear Magnetic Resonance.

A2E-induced inflammation and angiogenesis in RPE cells in vitro are modulated by PPAR-α, -ß/δ, -γ, and RXR antagonists and by norbixin.

Systemic administration of the di-apocarotenoid norbixin (BIO201) is neuroprotective, preserves photoreceptor function and inhibits A2E and lipofuscin accumulation in animal models of age-related macular degeneration and Stargardt disease.

Beyond AREDS Formulations, What Is Next for Intermediate Age-Related Macular Degeneration (iAMD) Treatment?

Biophytis Announces it Presented One Oral and One Poster Presentation at the MaculART meeting in Paris, France.

Chronic oral treatment with BIO201 preserves retinal function in a dry AMD experimental model.

Involvement of peroxisome proliferator activator receptors (PPARs) in the photoprotective activity of the di-apo-carotenoid norbixin.

Evidence for the involvement of PPARs in the photoprotective activity of BIO201 (norbixin) on retinal pigment epithelium.

Norbixin Protects Retinal Pigmented Epithelium Cells and Photoreceptors against A2E-Mediated Phototoxicity In Vitro and In Vivo.